Neurexis Therapeutics

Neurexis Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, operating in the RNA & Gene Therapy sector. The company is advancing tatCN19o, an optimized peptide therapeutic designed to directly prevent neurodegeneration and restore function by targeting a critical node in the glutamate excitotoxicity pathway. Its strategy targets multiple high-value CNS indications with no approved neuroprotective therapies, representing large, untreated markets. The company appears to be in an early development stage, likely supported by venture or incubator funding.

Optimized peptide therapeutics (e.g., tatCN19o) designed to cross the blood-brain barrier and inhibit key signaling molecules (likely CaMKII) downstream of glutamate excitotoxicity, aiming for both neuroprotection and functional restoration.

Operates in the highly competitive and high-failure neuroprotection space, competing against numerous biopharma companies exploring various mechanisms (e.g., apoptosis inhibitors, anti-inflammatories, cell therapies). Differentiation hinges on tatCN19o's dual mechanism of protection and functional restoration via a specific CaMKII target.